Found 17 clinical trials
Pneumococcal Infection
(V110) and, a 15-valent pneumococcal conjugate vaccine (PCV) indicated for the prevention of invasive pneumococcal disease (V114).
- 0 views
- 13 Jan, 2022
- 1 location
Pneumococcal Infection
(V110) and, a 15-valent pneumococcal conjugate vaccine (PCV) indicated for the prevention of invasive pneumococcal disease (V114).
- 0 views
- 18 Apr, 2022
- 1 location
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccines(RIV).
- 268 views
- 12 May, 2022
- 30 locations
Dynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens
The investigators seek to conduct a prospective, longitudinal study to identify the dynamic changes in nasopharyngeal (NP) colonization patterns and acute otitis media (AOM) etiology involving antibiotic-resistant Streptococcus pneumoniae (Spn) and Haemophilus influenzae (Hflu).
- 0 views
- 23 Jul, 2021
- 1 location
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a …
- 0 views
- 06 May, 2022
- 8 locations
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Primary objectives: To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection). To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups …
- 35 views
- 13 May, 2022
- 53 locations
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Primary objectives: To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection). To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups …
- 31 views
- 13 May, 2022
- 53 locations
Nasopharyngeal Carriage of S. Pneumoniae
the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae serotypes in children
- 0 views
- 31 Mar, 2021
- 1 location
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
(V110) and, a 15-valent pneumococcal conjugate vaccine (PCV) indicated for the prevention of invasive pneumococcal disease (V114).
- 0 views
- 01 May, 2022
- 42 locations
Evaluation of PCV Schedules in a Naive Population in Vietnam
The cost of pneumococcal conjugate vaccine use can be greatly reduced by making use of existing herd immunity to protect children against vaccine type pneumococci. The investigators will reduce
- 0 views
- 19 Jun, 2021
- 1 location
- 1
- 2